Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp; Kristian Reich; Craig L. Leonardi; Leon Kircik; Sergio Chimenti; Richard G.B. Langley; Chia Chi Hu; Randall M. Stevens; Robert M. Day; Kenneth B. Gordon; Neil J. Korman; Christopher E.M. Griffiths

doi:10.1016/j.jaad.2015.03.049

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G.B. Langley, Chia Chi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, Christopher E.M. Griffiths

Inernational Relations Division

科研成果: 期刊稿件 › 文章 › 同行评审

513 引用（Scopus）

源语言	英语
页（从-至）	37-49
页数	13
期刊	Journal of the American Academy of Dermatology
卷	73
期	1
DOI	https://doi.org/10.1016/j.jaad.2015.03.049
出版状态	已出版 - 7月 1 2015

!!!ASJC Scopus Subject Areas

皮肤医学

访问文件

10.1016/j.jaad.2015.03.049

其它文件与链接

指纹

探究 'Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)' 的科研主题。它们共同构成独一无二的指纹。

引用此

Papp, K., Reich, K., Leonardi, C. L., Kircik, L., Chimenti, S., Langley, R. G. B., Hu, C. C., Stevens, R. M., Day, R. M., Gordon, K. B., Korman, N. J., & Griffiths, C. E. M. (2015). Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). Journal of the American Academy of Dermatology, 73(1), 37-49. https://doi.org/10.1016/j.jaad.2015.03.049

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). / Papp, Kim; Reich, Kristian; Leonardi, Craig L. 等.
在: Journal of the American Academy of Dermatology, 卷 73, 号码 1, 01.07.2015, 页码 37-49.

科研成果: 期刊稿件 › 文章 › 同行评审

Papp, K, Reich, K, Leonardi, CL, Kircik, L, Chimenti, S, Langley, RGB, Hu, CC, Stevens, RM, Day, RM, Gordon, KB, Korman, NJ & Griffiths, CEM 2015, 'Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)', Journal of the American Academy of Dermatology, 卷 73, 号码 1, 页码 37-49. https://doi.org/10.1016/j.jaad.2015.03.049

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB 等. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). Journal of the American Academy of Dermatology. 2015 7月 1;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049

Papp, Kim ; Reich, Kristian ; Leonardi, Craig L. 等. / Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis : Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). 在: Journal of the American Academy of Dermatology. 2015 ; 卷 73, 号码 1. 页码 37-49.

@article{907cdd3214ad4deca1b17af708e74f50,

title = "Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)",

keywords = "ESTEEM, apremilast, clinical trial, phosphodiesterase 4 inhibitor, psoriasis, treatment",

author = "Kim Papp and Kristian Reich and Leonardi, {Craig L.} and Leon Kircik and Sergio Chimenti and Langley, {Richard G.B.} and Hu, {Chia Chi} and Stevens, {Randall M.} and Day, {Robert M.} and Gordon, {Kenneth B.} and Korman, {Neil J.} and Griffiths, {Christopher E.M.}",

note = "Publisher Copyright: {\textcopyright} 2015 American Academy of Dermatology, Inc.",

year = "2015",

month = jul,

day = "1",

doi = "10.1016/j.jaad.2015.03.049",

language = "English",

volume = "73",

pages = "37--49",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "1",

}

TY - JOUR

T1 - Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis

T2 - Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

AU - Papp, Kim

AU - Reich, Kristian

AU - Leonardi, Craig L.

AU - Kircik, Leon

AU - Chimenti, Sergio

AU - Langley, Richard G.B.

AU - Hu, Chia Chi

AU - Stevens, Randall M.

AU - Day, Robert M.

AU - Gordon, Kenneth B.

AU - Korman, Neil J.

AU - Griffiths, Christopher E.M.

PY - 2015/7/1

Y1 - 2015/7/1

KW - ESTEEM

KW - apremilast

KW - clinical trial

KW - phosphodiesterase 4 inhibitor

KW - psoriasis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84937880965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937880965&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2015.03.049

DO - 10.1016/j.jaad.2015.03.049

M3 - Article

C2 - 26089047

AN - SCOPUS:84937880965

SN - 0190-9622

VL - 73

SP - 37

EP - 49

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -